WEHI-539
WEHI-539 is a selective inhibitor of Bcl-XL with an IC50 of 1.1 nM.
Product Specifications
CAS Number
1431866-33-9
UNSPSC
12352005
Hazard Statement
H302, H312, H332
Target
Bcl-2 Family
Type
Reference compound
Related Pathways
Apoptosis
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/WEHI-539.html
Purity
95.05
Solubility
10 mM in DMSO
Smiles
OC(C1=C(CCCOC2=CC=C(CN)C=C2)SC(C3=CC4=C(CCC/C4=N\NC5=NC(C=CC=C6)=C6S5)C=C3)=N1)=O
Molecular Formula
C31H29N5O3S2
Molecular Weight
583.72
Precautions
H302, H312, H332
References & Citations
[1]Lessene G, et al. Structure-guided design of a selective BCL-X (L) inhibitor. Nat Chem Biol. 2013 Jun;9 (6) :390-7.|[2]Abed MN, et al. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. J Ovarian Res. 2016 Apr 14;9:25.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
Bcl-xL
Citation 01
Am J Cancer Res. 2019 Dec 1;9 (12) :2580-2598.|Breast Cancer Res Treat. 2019 Feb;173 (3) :585-596.|Cancer Biology. 2020 May.|Cell Death Differ. 2014 Jul;21 (7) :1170-7. |Cell Death Differ. 2017 Jan;24 (1) :111-119. |Cell Death Dis. 2017 Dec 13;8 (12) :3216.|Cell Death Dis. 2023 Oct 28;14 (10) :705.|Cell. 2014 Dec 18;159 (7) :1549-62.|Clin Cancer Res. 2019 Dec 1;25 (23) :7139-7150. |J Ovarian Res. 2016 Apr 14;9 (1) :25. |Nat Commun. 2016 Mar 9;7:10916.|Nature. 2017 Nov 9;551 (7679) :247-250. |Oncol Rep. 2019 Dec;42 (6) :2416-2425.|Pharmacol Res. 2023 Jan:187:106628.|Acta Pharmacol Sin. 2024 Nov;45 (11) :2420-2431.|bioRxiv. 2023 Aug 5.|Blood. 2014 Dec 4;124 (24) :3587-96. |Cell Death Dis. 2018 Jan 19;9 (2) :42.|Cell Rep. 2023 Mar 30;42 (4) :112324.|Cell. 2014 Dec 18;159 (7) :1549-62.|Immunity. 2024 Jun 11;57 (6) :1289-1305.e9.|Int J Cancer. 2018 Feb 1;142 (3) :584-596.|Malays Appl Biol. (2020) 49 (1) : 193-197.|Methods Mol Biol. 2018:1711:351-398.|Mol Cancer Ther. 2025 Jul 10.|Nat Biotechnol. 2018 Feb;36 (2) :179-189.|Nat Cancer. 2024 Jul;5 (7) :1082-1101.|Nat Chem Biol. 2022 Jun;18 (6) :615-624.|Nature. 2017 Nov 9;551 (7679) :247-250. |Oncotarget. 2018 May 25;9 (40) :26046-26063.|The Department of Medical Sciences, Harvard University. 2019 Dec.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS7172487 Inquire
Rabbit anti-Escherichia coli O157:H7 (strain EC4115/EHEC) GUAC Polyclonal Antibody
Sign In for Pricing
View Details K3949104 1.0 µg DNA
Mocs2 sgRNA CRISPR Lentivector (Mouse) (Target 3)
Sign In for Pricing
View Details GTR15365124 1 Vial
Lentiviral human HOTS sgRNA gene knockout kit - Lentiviral human HOTS sgRNA gene knockout kit (25)
Sign In for Pricing
View Details 
K1673602 1.0 µg DNA
PMM2 sgRNA CRISPR Lentivector (Human) (Target 1)
Sign In for Pricing
View Details 